Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

Autor: Cathrine Lund Lorentzen, Evelina Martinenaite, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Sofie Kirial Mørk, Ayako Wakatsuki Pedersen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

BackgroundArginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of arginase-1-expressing cells could potentially restore L-arginine levels a

Externí odkaz: https://doaj.org/article/0746d310421f4a54b6021f1392b47672

Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab

Autor: Julie W. Kjeldsen, Cathrine L. Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Eva Ehrnrooth, Mads H. Andersen, Inge Marie Svane

Publikováno v: Cancer Research. 82:CT535-CT535

Background: Immunotherapy is an effective treatment for patients with metastatic melanoma. However, immune checkpoint inhibitors (ICI) often induce immune-related adverse events and despite high response rates many patients still progress. Nivolumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef75e7ef4951b06312a3e17e0e43272f
https://doi.org/10.1158/1538-7445.am2022-ct535

Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non–small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC)

Autor: Jonathan W. Riess, Paul Shaw, Devraj Srinivasan, Pilar Garrido, Jacqueline Vuky, Marya F. Chaney, Shane O'Neill, Alireza Alavi, Diane Opatt McDowell, Eva Ehrnrooth, Ezra Cohen

Publikováno v: Journal of Clinical Oncology. 40:TPS2699-TPS2699

TPS2699 Background: Immunotherapy has transformed the treatment of NSCLC and other solid tumors, such as SCCHN and UBC. However, even with standard-of-care anti-PD-1/PD-L1 therapies, few patients achieve durable benefit even when PD-L1 is overexpress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::887efffadae1b37f2b30eae91bfed38a
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2699

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Autor: Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, Morten Orebo Holmström, Helle Westergren Hendel, Eva Ehrnrooth, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen, Inge Marie Svane

Publikováno v: Kjeldsen, J W, Lorentzen, C L, Martinenaite, E, Ellebaek, E, Donia, M, Holmstroem, R B, Klausen, T W, Madsen, C O, Ahmed, S M, Weis-Banke, S E, Holmström, M O, Hendel, H W, Ehrnrooth, E, Zocca, M B, Pedersen, A W, Andersen, M H & Svane, I M 2021, ' A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma ', Nature Medicine, vol. 27, pp. pages2212–2223 . https://doi.org/10.1038/s41591-021-01544-x

Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dd3bba1301f4d5d79e0b554e5fade1b
https://curis.ku.dk/ws/files/314958988/s41591_021_01544_x.pdf

Evaluation of the VeriStrat

Autor: Shirish, Gadgeel, Glenwood, Goss, Jean-Charles, Soria, Enriqueta, Felip, Vassilis, Georgoulias, Shun, Lu, Manuel, Cobo, Konstantinos, Syrigos, Ki Hyeong, Lee, Erdem, Göker, Salih Z, Guclu, Dolores, Isla, Alessandro, Morabito, Nicholas, Dupuis, Claudia, Bühnemann, Nicole, Krämer, Flavio, Solca, Eva, Ehrnrooth, Andrea, Ardizzoni

Publikováno v: Lung cancer (Amsterdam, Netherlands). 109

Identification of biomarkers associated with clinical benefit may be crucial in establishing optimal treatment choice for patients with squamous cell carcinoma (SCC) of the lung after first-line chemotherapy. In this study, the ability of the VeriStr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::08df8e82ebd5a203a0dcf458db939d58
https://pubmed.ncbi.nlm.nih.gov/28577938